Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Report documents
-
Extract of dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Dossier assessment
Adults with multiple myeloma who have received at least one prior therapy
- Patients with ISS stage II or III: proof of considerable added benefit
- Patients with ISS stage I: proof of minor added benefit
Project details
- Project no.
- A22-40
- Commission
- Commission awarded on 01.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, ineligible for stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (newly diagnosed multiple myeloma, suitable for autologous stem cell transplant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed